JP2024502270A - エストロゲン受容体調節薬 - Google Patents

エストロゲン受容体調節薬 Download PDF

Info

Publication number
JP2024502270A
JP2024502270A JP2023538760A JP2023538760A JP2024502270A JP 2024502270 A JP2024502270 A JP 2024502270A JP 2023538760 A JP2023538760 A JP 2023538760A JP 2023538760 A JP2023538760 A JP 2023538760A JP 2024502270 A JP2024502270 A JP 2024502270A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
mmol
acceptable salt
compound
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023538760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024502270A5 (https=
Inventor
チャン，グオバオ
キンファ ファン，ピーター
デュアン バンカー，ケビン
ガジャナン ヘグデ，サイー
Original Assignee
リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー filed Critical リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー
Publication of JP2024502270A publication Critical patent/JP2024502270A/ja
Publication of JP2024502270A5 publication Critical patent/JP2024502270A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023538760A 2020-12-23 2021-12-17 エストロゲン受容体調節薬 Pending JP2024502270A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063130123P 2020-12-23 2020-12-23
US63/130,123 2020-12-23
US202163164095P 2021-03-22 2021-03-22
US63/164,095 2021-03-22
US202163265052P 2021-12-07 2021-12-07
US63/265,052 2021-12-07
PCT/US2021/072983 WO2022140744A1 (en) 2020-12-23 2021-12-17 Estrogen receptor modulators

Publications (2)

Publication Number Publication Date
JP2024502270A true JP2024502270A (ja) 2024-01-18
JP2024502270A5 JP2024502270A5 (https=) 2024-12-25

Family

ID=81656364

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023538760A Pending JP2024502270A (ja) 2020-12-23 2021-12-17 エストロゲン受容体調節薬

Country Status (5)

Country Link
US (2) US11339162B1 (https=)
EP (1) EP4267578A4 (https=)
JP (1) JP2024502270A (https=)
TW (1) TW202241886A (https=)
WO (1) WO2022140744A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4267578A4 (en) * 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
TW202317539A (zh) * 2021-07-15 2023-05-01 大陸商四川海思科製藥有限公司 芳氨基衍生物雌激素受體調節劑及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014191726A1 (en) * 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds
WO2017172957A1 (en) * 2016-04-01 2017-10-05 Kalyra Pharmaceuticals, Inc. Estrogen receptor modulators

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177443B1 (en) 1997-03-07 2001-01-23 Novo Nordisk A/S 4,5,6,7-tetrahydro-thieno[3, 2-C]pyridine derivatives, their preparation and use
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
US6720330B2 (en) 2000-11-17 2004-04-13 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
JP2005508968A (ja) 2001-10-19 2005-04-07 トランス　テック　ファーマ，インコーポレイテッド ＰＴＰ阻害剤としてのβ−カルボリン誘導体
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
UA92317C2 (ru) 2004-03-15 2010-10-25 Пи-Ти-Си ТЕРАПЬЮТИКС, ИНК. Производные карболина, пригодные для ингибирования развития кровеносных сосудов
WO2006058088A2 (en) 2004-11-23 2006-06-01 Ptc Therapeutics, Inc. Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
EP1829874B1 (en) 2004-12-22 2014-02-12 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
WO2010107485A1 (en) 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York E3 ligase inhibitors
WO2010138685A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating prostate conditions
US20120202801A1 (en) 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
MX373926B (es) 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
WO2011103487A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011150162A1 (en) 2010-05-27 2011-12-01 Ptc Therapeutics, Inc. Methods for treating viral conditions
RS56042B1 (sr) 2010-06-10 2017-09-29 Seragon Pharmaceuticals Inc Modulatori estrogenih receptora i njihove upotrebe
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
US9499538B2 (en) 2012-03-20 2016-11-22 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
ES2671516T3 (es) 2013-02-19 2018-06-06 Novartis Ag Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
MX2015011132A (es) 2013-03-14 2015-11-30 Seragon Pharmaceuticals Inc Moduladores policiclicos del receptor de estrogenos y sus usos.
EP3089747A1 (en) 2013-12-06 2016-11-09 F. Hoffmann-La Roche AG Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
MX388871B (es) 2014-06-27 2025-03-20 Nogra Pharma Ltd Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
WO2016069949A1 (en) 2014-10-29 2016-05-06 Virginia Tech Intellectual Properties, Inc. Compositions and formulations of methylerthritol phosphate pathway inhibitors and uses thereof
TWI874834B (zh) * 2014-12-18 2025-03-01 瑞士商赫孚孟拉羅股份公司 四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
KR20240142622A (ko) 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
EP3472162B1 (en) 2016-06-16 2021-11-17 F. Hoffmann-La Roche AG Heteroaryl estrogen receptor modulators and uses thereof
WO2018130123A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的五环类化合物及其应用
WO2018130124A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
AU2018347307A1 (en) 2017-10-09 2020-04-23 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
CN109867659A (zh) 2017-12-04 2019-06-11 江苏恒瑞医药股份有限公司 苯并哌啶类衍生物的制备方法
CN111601797B (zh) 2018-05-23 2022-11-22 江苏恒瑞医药股份有限公司 苯并哌啶或杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
CR20200621A (es) * 2018-06-21 2021-02-03 Hoffmann La Roche Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
JP7571006B2 (ja) 2018-08-17 2024-10-22 ジェネンテック， インコーポレイテッド 乳がんの処置のための診断的および治療的方法
KR20220044528A (ko) 2019-08-06 2022-04-08 리커리엄 아이피 홀딩스, 엘엘씨 돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
AU2020380211A1 (en) 2019-11-04 2022-05-19 Recurium Ip Holdings, Llc Salts and forms of an estrogen receptor modulator
WO2021216671A1 (en) 2020-04-22 2021-10-28 Recurium Ip Holdings, Llc Preparation of an selective estrogen receptor degrader
EP4267578A4 (en) * 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014191726A1 (en) * 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds
WO2017172957A1 (en) * 2016-04-01 2017-10-05 Kalyra Pharmaceuticals, Inc. Estrogen receptor modulators

Also Published As

Publication number Publication date
US11999728B2 (en) 2024-06-04
US20220235050A1 (en) 2022-07-28
US11339162B1 (en) 2022-05-24
TW202241886A (zh) 2022-11-01
EP4267578A1 (en) 2023-11-01
WO2022140744A1 (en) 2022-06-30
EP4267578A4 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
AU2020294196B2 (en) Estrogen receptor modulators
KR102737181B1 (ko) Jak 억제제 및 그 제조방법과 의약분야에서의 응용
KR102751751B1 (ko) 벤즈아미드 화합물
JP7794448B2 (ja) 組み合わせ
CA3037064A1 (en) Spirocyclic compounds
KR20220034805A (ko) Bcl-2 단백질 억제제
CA3165382A1 (en) Combinations
JP7750526B2 (ja) 組み合わせ
KR20220119419A (ko) 복합제
JP2018515524A (ja) 二環式化合物
JP2024502270A (ja) エストロゲン受容体調節薬
CN116964049A (zh) 雌激素受体调节剂
RU2845443C1 (ru) Комбинации
JP2023508324A (ja) 組み合わせ
JP2020529403A (ja) アクリル酸類似体
BR112018070161B1 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso dos mesmos e método para inibir o crescimento de célula

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241217

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20241217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250701